Eli Lilly Alzheimer - Search News

Eli Lilly Alzheimer’s drug rejected

Wall Street Journal · 2d

England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side effects.

Reuters on MSN · 2d

UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.

Business Insider · 2d

Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being

FierceBiotech1d

Eisai, Eli Lilly didn't disclose heightened brain injury risk to Alzheimer's trial patients: NYT

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

1d

Novo Nordisk's semaglutide could also be effective against Alzheimer's

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

1don MSN

Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

The Financial Express13h

Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData

There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results